english.prescrire.org > Spotlight > 100 most recent > In the May issue of Prescrire International - Simeprevir (Olysio°) in chronic hepatitis C: an option for some patients

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

In the May issue of Prescrire International - Simeprevir (Olysio°) in chronic hepatitis C: an option for some patients

FREE DOWNLOAD When triple-drug therapy is considered for chronic hepatitis C due to HCV genotype 1 but sofosbuvir cannot be used, simeprevir seems preferable to other viral protease inhibitors when the virus does not harbour the Q80K substitution.
Full text available for free download.

Summary

  • Simeprevir is active in patients with hepatitis C due to genotype I strains lacking the Q80K substitution.
     
  • When triple-agent therapy is warranted but sofosbuvir cannot be used, adding simeprevir to the peginterferon alfa-ribavirin combination increases the chances of achieving a sustained virological response.
     
  • Simeprevir is slightly better tolerated than boceprevir and telaprevir.
     
  • The efficacy of simeprevir on other genotypes was not known in late 2014.

Full text available for free download.

 ©Prescrire 1 May 2015

"Simeprevir (Olysio°). Chronic hepatitis C: an option for some patients" Prescrire Int 2015; 24 (160): 120. (Pdf, free)
Download the full review
Pdf, free